Senseonics Holdings, Inc. Reports Preliminary Second Quarter 2019 Net Revenue
Summary
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (“Senseonics” or “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced preliminary financial results for the second quarter of 2019. “Patient demand is strong, and we are successfully accelerating shipments and prescriptions globally, thus increasing our confidence in greater adoption of Eversense in the second half of the year.” The foregoing expected results are preliminary and are subject to change based on the completion of Senseonics’ quarter-end review process. These preliminary financial results include calculations or figures that have been prepared internally by management and have not been reviewed or audited by the Company’s auditors. Senseonics plans to release complete second quarter 2019 financial results on Wednesday, August 7, 2019 at 4:30 pm ET. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: potential adjustments in the Company’s reported financial results as a result of the conclusion of the Company’s quarterly financial reporting process, including the review of the Company’s quarterly financial statements by the Company’s independent registered public accounting firm, uncertainties inherent in the commercial launch and commercial expansion of the product, and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2018, Senseonics’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof.